Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24,13:00-15:20
Collaboration Between North American and Chinese Innovative Drug Industries
Stay tuned
Planner:
Yingchun Zhao:Founder, PolyEngine Technologies; Partner, Beijing BioInno Technology; Vice President, SAPA-DC
James Bo:International Institute of Applied Technology (IATRI)
13:00-13:10 Opening Remarks: China Innovative Drug Globalization 2.0: Building a New FDA-Ready Industrialization Paradigm
Victor Liang:Partner, Beijing BioInno Technology; Co-founder, Nuraydia Life Sciences
13:10-13:20 From China R&D to FDA IND: The First Gateway to Global Drug Development
Jinhui Dou:Consultant, JP Consulting Group
13:20-13:30 From IND Clearance to Patient Enrollment: Building North American Clinical Development Capabilities
Jane Fang:Founder & CEO, Polaris Strategic Partners
13:30-13:40 From AI Prediction to Real-World Evidence: How AIDD Enables End-to-End Acceleration of FDA-Ready Drug Candidates
Dr. Rico W. Tang:Chief Science Advisor, AIDM
13:40-13:50 AI-Native Clinical Development: Reconstructing the Future Clinical Decision-Making System
Will Ma:Founder & CEO, HopeAI
13:50-14:00 From Data to Decisions: How AI is Transforming Clinical Statistics and Regulatory Deliverables
Oliver Li:Co-founder & Head of Product, Hill Research
14:00-14:10 A New Paradigm for Pharmacovigilance in the FDA Era: Intelligent Safety Monitoring Powered by Knowledge Graphs and Large Language Models
Kaixian Yu:Founder & CEO, MedGraph Intelligence
14:10-14:20 From Patient Navigation to Global Trial Acceleration: How Digital Health is Transforming Clinical Development
Frank Chen:President & CEO, LINKMedicine.AI
14:20-14:30 Innovation and Practice in Nucleic Acid Therapeutics: From Technological Breakthroughs to Commercialization
Shawn Pan:CBO, Cosynbio
14:30-15:20 China Innovative Drug Globalization 2.0: How to Build FDA-Ready North American Industrialization Capabilities?
Victor Liang(Host):Partner, Beijing BioInno Technology; Co-founder, Nuraydia Life Sciences
Charles Li:Co-founder & CEO, Nuraydia Life Sciences; Partner, Beijing BioInno Technology
Jinhui Dou:Consultant, JP Consulting Group
Jane Fang:Founder & CEO, Polaris Strategic Partners
Will Ma:Founder & CEO, HopeAI
Dr. Rico W. Tang:Chief Science Advisor, AIDM
Oliver Li:Co-founder & Head of Product, Hill Research
Kaixian Yu:Founder & CEO, MedGraph Intelligence
Shawn Pan:CBO, Cosynbio